Diagnosis and Management of Acute Coronary Syndrome: An Evidence-Based Update
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Acute coronary syndrome (ACS) describes the range of myocardial ischemic states that includes unstable angina, non-ST elevated myocardial infarction (MI), or ST-elevated MI. ACS is associated with substantial morbidity and mortality and places a large financial burden on the health care system. The diagnosis of ACS begins with a thorough clinical assessment of a patient's presenting symptoms, electrocardiogram, and cardiac troponin levels as well as a review of past medical history. Early risk stratification can assist clinicians in determining whether an early invasive management strategy or an initial conservative strategy should be pursued and can help determine appropriate pharmacologic therapies. Key components in the management of ACS include coronary revascularization when indicated; prompt initiation of dual antiplatelet therapy and anticoagulation; and consideration of adjuvant agents including β blockers, inhibitors of the renin angiotensin system, and HmG-coenzyme A reductase inhibitors. It is essential for clinicians to take an individualized approach to treatment and consider long-term safety and efficacy when managing patients with a history of ACS after hospital discharge.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663 · cited 1×
“Patients with stable CAD who are not medically optimized (ie, cannot tolerate a -blocker or statin), who are not able to be revascularized, and/or who have poorly controlled diabetes have shown mortality benefit with continued treatment with ACE inhibitors.(40) On the contrary, revascularized patients with stable CAD,…”
BackgroundWriting Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790 · cited 1×
“Patients with a history of stroke or transient ischemic attack had net harm with the use of prasugrel, and therefore its use in these patients is contraindicated.(18) This trial was conducted in patients with moderate-to-high risk UA, NSTEMI, or STEMI who were referred for PCI, and prasugrel is U.”
Method(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470 · cited 1×
“001 with a number needed to harm (NNH) of 100 patients (level of evidence 1).(17)”
BackgroundPfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911 · cited 1×
“36–39 ACE inhibitors have also been studied in patients with stable CAD, which have shown conflicting effects on mortality and vascular events (level of evidence 2).”
BackgroundTarver, T. (2014) · Journal of Consumer Health On the Internet · doi:10.1080/15398285.2014.902284 · Cited by 5,605
Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
WRITING COMMITTEE MEMBERS*, O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182742cf6 · Cited by 4,725 · cited 11×
“There has been a substantial reduction in the incidence of STEMI and a subsequent increase in the incidence of NSTEMI.(3) An analysis of 46,086 hospitalizations for ACS in a study conducted by Kaiser Permanente demonstrated that the percentage of STEMI cases decreased from 48.”
BackgroundMethodInfluentialBraunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
Third universal definition of myocardial infarction
Thygesen, K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., Chaitman, B. R., White, H. D., the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction, Authors/Task Force Members Chairpersons, Thygesen, K., Alpert, J. S., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs184 · Cited by 3,058
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927 · cited 1×
“Aldosterone antagonists (ie, spironolactone, eplerenone) have also been studied in the post-ACS setting and have been found to reduce morbidity and mortality in select patient populations (level of evidence 1).(43,44) Initiation of an aldosterone antagonist is recommended after an ACS event for patients who are on the…”
BackgroundHeart disease and stroke statistics--2013 update: a report from the American Heart Association.
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · eScholarship (California Digital Library) · Cited by 2,601
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67660-x · Cited by 1,858 · cited 1×
“investigating the impact of -blockers on mortality in patients with ACS have variable results based on differences in route of administration, time of administration from event onset, and patient population.(33,34) There is, however, sufficient evidence to recommend -blockers as a routine part of care in this patient…”
BackgroundAnderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181940 · Cited by 1,853
(2001) · The Lancet · doi:10.1016/s0140-6736(00)04560-8 · Cited by 1,837 · cited 1×
“investigating the impact of -blockers on mortality in patients with ACS have variable results based on differences in route of administration, time of administration from event onset, and patient population.(33,34) There is, however, sufficient evidence to recommend -blockers as a routine part of care in this patient…”
BackgroundKøber, L., Torp-Pedersen, C., Carlsen, J. E., Bagger, H., Eliasen, P., Lyngborg, K., Videbæk, J., Cole, D. S., Auclert, L., Pauly, N. C., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512213332503 · Cited by 1,773
Early Diagnosis of Myocardial Infarction with Sensitive Cardiac Troponin Assays
Reichlin, T., Hochholzer, W., Bassetti, S., Steuer, S., Stelzig, C., Hartwiger, S., Biedert, S., Schaub, N., Buerge, C., Potocki, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900428 · Cited by 1,687 · cited 2×
“Cardiac troponins are biochemical markers of myocardial damage.(6) Increases in cardiac biomarkers, notably cardiac troponin (I or T), or the MB fraction of creatine kinase (CKMB), signify myocardial injury leading to necrosis of myocardial cells.”
BackgroundAngiotensin-converting-enzyme inhibition in stable coronary artery disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa042739 · Cited by 1,123 · cited 1×
“On the contrary, revascularized patients with stable CAD, without significant comorbidities, who are on optimal medication management, have not shown this long-term benefit.(42) The decision to continue an ACE inhibitor long-term in patients with a history of ACS should be individualized with concomitant disease state…”
BackgroundGRUPPOITALIANOPERLOSTUDIODELL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90232-1 · Cited by 1,118
Collins, R. T., Peto, R., Flather, M. D., Parish, S., Sleight, P., Conway, M. A., Pipilis, A., Baigent, C., Barnett, D., Boissel, J., et al. (1995) · Ghent University Academic Bibliography (Ghent University) · Cited by 1,115
2012 Writing Committee Members, Jneid, H., Anderson, J. L., Wright, R. S., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318256f1e0 · Cited by 1,090
Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
Alexander, J. H., Lopes, R. D., James, S., Kilaru, R., He, Y., Mohan, P., Bhatt, D. L., Goodman, S., Verheugt, F. W., Flather, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105819 · Cited by 1,005
Vorapaxar in the Secondary Prevention of Atherothrombotic Events
Morrow, D. A., Braunwald, E., Bonaca, M. P., Ameriso, S. F., Dalby, A. J., Fish, M. P., Fox, K. A. A., Lipka, L. J., Liu, X., Nicolau, J. C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200933 · Cited by 948 · cited 1×
“The role of vorapaxar in the management of ACS has not been fully elucidated and will likely evolve in the coming years.(21)”
BackgroundMehta, S. R., Tanguay, J.-F., Eikelboom, J. W., Jolly, S. S., Joyner, C. D., Granger, C. B., Faxon, D. P., Rupprecht, H.-J., Budaj, A., Avezum, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61088-4 · Cited by 825 · cited 1×
“Aspirin 81 mg daily is a reasonable maintenance dosing regimen given that higher doses have not shown any benefit over low-dose aspirin (level of evidence 1).(13) In addition to aspirin, a P2Y12 antagonist should be added for patients with ACS who are medically managed as well as those undergoing PCI (strength of reco…”
BackgroundThird universal definition of myocardial infarction
Thygesen, K., Alpert, J. S., & White, H. D. (2013) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2013.10.002 · Cited by 719
The rational clinical examination
Devitt, N. F. (1992) · JAMA · doi:10.1001/jama.268.16.2164c · Cited by 616
Oldgren, J., Budaj, A., Granger, C. B., Khder, Y., Roberts, J., Siegbahn, A., Tijssen, J. G. P., Van de Werf, F., Wallentin, L., & for the RE-DEEM Investigators (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr113 · Cited by 534
Differential diagnosis of elevated troponins
Korff, S., Katus, H. A., & Giannitsis, E. (2006) · Heart · doi:10.1136/hrt.2005.071282 · Cited by 388
Pitt, B., Williams, G., Remme, W., Martinez, F., Lopez-Sendon, J., Zannad, F., Neaton, J., Roniker, B., Hurley, S., Burns, D., et al. (2001) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1011119003788 · Cited by 364 · cited 1×
“Aldosterone antagonists (ie, spironolactone, eplerenone) have also been studied in the post-ACS setting and have been found to reduce morbidity and mortality in select patient populations (level of evidence 1).(43,44) Initiation of an aldosterone antagonist is recommended after an ACS event for patients who are on the…”
BackgroundAndreotti, F., Testa, L., Biondi-Zoccai, G. G. L., & Crea, F. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi485 · Cited by 289 · cited 1×
“00001), representing an NNH of 100 patients to cause a major bleed.(23) While not routinely used in clinical practice, warfarin is FDA approved for reducing the risk of death, recurrent MI, and thromboembolic events after MI.”
BackgroundIs This Patient Having a Myocardial Infarction?
Panju, A. A. (1998) · JAMA · doi:10.1001/jama.280.14.1256 · Cited by 287
(2001) · New England Journal of Medicine · doi:10.1056/nejm200111153452023 · Cited by 238
Fesmire, F. M., Percy, R. F., Bardoner, J. B., Wharton, D. R., & Calhoun, F. B. (1998) · Annals of Emergency Medicine · doi:10.1016/s0196-0644(98)70274-4 · Cited by 214 · cited 1×
“Similar to cardiac biomarkers, the ECG alone is often insufficient to make the diagnosis of an acute MI, and the sensitivity and specificity of ECG are increased by serial assessments.(9) ECG changes such as ST deviation may be present in other conditions, such as left ventricular hypertrophy, left bundle branch block…”
Navarese, E. P., Gurbel, P. A., Andreotti, F., Tantry, U., Jeong, Y.-H., Kozinski, M., Engstrøm, T., Di Pasquale, G., Kochman, W., Ardissino, D., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-4-201302190-00006 · Cited by 174 · cited 1×
“180).(10) Early invasive coronary angiography is recommended in NSTEMI/UA patients with refractory angina or hemodynamic or electric instability (strength of recommendation A).”
BackgroundEarly Diagnosis of Myocardial Infarction with Sensitive Cardiac Troponin Assays
Mueller, C. E., Twerenbold, R., & Reichlin, T. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2018.298638 · Cited by 140
Balk, E. M., Ioannidis, J. P. A., Salem, D. N., Chew, P. W., & Lau, J. (2001) · Annals of Emergency Medicine · doi:10.1067/mem.2001.114905 · Cited by 140
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
van der Harst, P., Voors, A. A., & van Veldhuisen, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejm200408123510719 · Cited by 122
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Gersh, B. J. (2010) · Yearbook of Cardiology · doi:10.1016/s0145-4145(09)79737-0 · Cited by 91
Kezerashvili, A., Marzo, K., & De Leon, J. (2012) · Current Cardiology Reviews · doi:10.2174/157340312801215764 · Cited by 81 · cited 1×
“If patients are experiencing side effects from -blocker use, it may be reasonable to discontinue therapy at least 1 year after an MI (strength of recommendation B).(35) For patients who are unable to take -blockers and experience recurrent ischemia, consideration should be given to starting a nondihydropyridine calciu…”
BackgroundAngiotensin-converting-enzyme inhibition in stable coronary artery disease
The PEACE Trial Investigators (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2005.02.062 · Cited by 61
PENDYALA, L. K., Torguson, R., Loh, J., Kitabata, H., Minha, S., Badr, S. M., Dvir, D., Barbash, I. M., Satler, L. F., Pichard, A. D., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(13)60079-0 · Cited by 58
Updates in Antiplatelet Agents Used in Cardiovascular Diseases
Cheng, J. W. M. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413499971 · Cited by 30 · cited 1×
“Well-established antiplatelet therapies in the management of ACS include aspirin, adenosine diphosphate P2Y12 receptor antagonists, and glycoprotein IIb/IIIa inhibitors.(12) Aspirin should be started as soon as possible after an ACS event with an initial loading dose of 162–325 mg, and should be continued indefinitely…”
BackgroundRole of Novel and Emerging Oral Anticoagulants for Secondary Prevention of Acute Coronary Syndromes
Ganetsky, V. S., Hadley, D. E., & Thomas, T. F. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1375 · Cited by 8 · cited 1×
“Although current guidelines do not recommend anticoagulants for post-ACS management following hospital discharge (unless indicated for a concomitant disease state), several studies have been conducted to investigate the use of anticoagulants in this setting (strength of recommendation B).(22) A meta-analysis including…”
Background
Metadata
- Authors
- Smith, J. N., Negrelli, J. M., Manek, M. B., Hawes, E. M., & Viera, A. J.
- Venue
- The Journal of the American Board of Family Medicine
- Published
- 2015-03-01
- Volume
- 28
- Issue
- 2
- Pages
- 283-293
- ISSN
- 1557-2625 (ISSN-L)
- 1558-7118
- OpenAlex
- W2099532869
- Cited by
- 170
- References
- 51
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.